The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04489264

Enrollment

Registered

2020-07-28

Start date

2020-11-30

Completion date

2025-11-30

Last updated

2020-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral T Cell Lymphoma

Keywords

Autologous Stem Cell Transplantation

Brief summary

The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 & PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.

Interventions

DRUGTransplant, Autologous

high dose chemotherapy followed by autologous stem cell transplantation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

* Patients with confirmed pathological diagnosis of aggressive PTCL * Age 18-65 years old * Achieving CR or PR after first-line therapy

Exclusion criteria

* Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.

Design outcomes

Primary

Measure	Time frame
PFS	2-year PFS

Countries

China

Contacts

Primary ContactJun Zhu, Dr.

zhu-jun2017@outlook.com+86-13910333346

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026